4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Gen WangSisi QinJacqueline ZayasJames N IngleMohan LiuRichard M WeinshilboumKunwei ShenLiewei WangPublished in: Breast cancer research and treatment (2019)
We identified ZNF423 regulated genes involved in the G2/M phase of the cell cycle. 4-OH-TAM sensitized ERα-positive breast cancer cells to docetaxel in a ZNF423 SNP-dependent manner. Our findings suggest that patients with rs9940645 variant genotype may benefit from concurrent tamoxifen and docetaxel. This would impact a substantial proportion of patients because this SNP has a minor allele frequency of 0.47.
Keyphrases
- estrogen receptor
- cell cycle
- positive breast cancer
- breast cancer cells
- genome wide
- locally advanced
- end stage renal disease
- cell proliferation
- high density
- chronic kidney disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- peritoneal dialysis
- dna methylation
- genetic diversity
- prognostic factors
- gene expression
- radiation therapy
- patient reported outcomes
- rectal cancer